Boothbay Fund Management’s aTyr Pharma ATYR Stock Holding History

Boothbay Fund Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-364	Closed	-$44K	–	1827
2025 Q1	$44K	Hold	364	–	–	﹤0.01%	1289
2024 Q4	$52.7K	Buy	+364	New	+$44.1K	﹤0.01%	1350
2023 Q4	–	Sell	-900	Closed	-$56.9K	–	2060
2023 Q3	$56.9K	Hold	900	–	–	﹤0.01%	1621
2023 Q2	$77.8K	Sell	900 -1,100	-55%	-$96K	﹤0.01%	1640
2023 Q1	$168K	Buy	+2,000	New	+$175K	﹤0.01%	1794
2021 Q4	–	Sell	-1,408	Closed	-$511K	–	2286
2021 Q3	$511K	Buy	1,408 +597	+74%	+$143K	0.01%	1072
2021 Q2	$158K	Hold	811	–	–	0.01%	1597
2021 Q1	$144K	Sell	811 -231	-22%	-$43.5K	0.01%	1432
2020 Q4	$162K	Buy	+1,042	New	+$152K	0.01%	1127
2019 Q2	–	Sell	-169	Closed	-$52K	–	920
2019 Q1	$52K	Hold	169	–	–	0.01%	700
2018 Q4	$47K	Hold	169	–	–	0.01%	591
2018 Q3	$77K	Sell	169 -18	-10%	-$7.88K	0.01%	734
2018 Q2	$95K	Buy	+187	New	+$177K	0.01%	687

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boothbay Fund Management's ATYR Position: Q2 2025 in Review

Boothbay Fund Management sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 364 shares — an estimated $44K sold.

Boothbay Fund Management first reported a position in ATYR in Q2 2018 and held it in 13 quarters. The position peaked at $511K in Q3 2021. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

Boothbay Fund Management reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
Boothbay Fund Management sold 364 aTyr Pharma shares in Q2 2025, an estimated $44K.
Boothbay Fund Management first reported a position in aTyr Pharma in Q2 2018 and held it in 13 quarters.
Boothbay Fund Management's aTyr Pharma position peaked at $511K in Q3 2021.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.